

Special Issue

State-of-the-Art Renal Diseases and Hypertension

Message from the Guest Editor

Recent advances in cardiovascular medicine have illuminated the complex relationship between high blood pressure (hypertension) and kidney function or disease. Hypertension can be both a cause and a consequence of kidney dysfunction, creating a vicious cycle that worsens cardiovascular risk. It emphasizes innovative diagnostic approaches, therapeutic strategies, and mechanistic insights. In addition to the well-recognized bidirectional interaction between hypertension and kidney dysfunction, it is increasingly important to consider independent yet often overlooked risk factors. For example, hyperinsulinemia associated with insulin resistance has the potential to induce hypertension and renal injury simultaneously. By drawing attention to this emerging area, the Special Issue aims to encourage submissions that explore its pathophysiological relevance and clinical implications. Overall, this Special Issue aims to present the latest perspectives on renal diseases and hypertension, focusing on disease mechanisms, contributing factors, and current and emerging treatment strategies.

Guest Editor

Prof. Dr. Pedro A. José

Medicine and Physiology/Pharmacology, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA

Deadline for manuscript submissions

30 September 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/273680

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).